Decisions made by the MHRA following investigations into complaints about advertising for licensed medicines.
Similar Posts
Field Safety Notices: 15 to 19 September 2025
List of Field Safety Notices from 15 to 19 September 2025.
Patients to benefit sooner as UK boosts clinical trials attractiveness with faster assessments and agile regulation
The MHRA is now setting out the next phase of reforms for 2026, aimed at helping patients access new cutting-edge treatments more quickly and boosting the UK’s competitiveness for global clinical research.
Transparency data: Medicines and Healthcare products Regulatory Agency GPC spending over £500: 2025-26
MHRA transactions over £500 made using the government procurement card (GPC).
MHRA Safety Roundup: December 2025
Summary of the latest safety advice for medicines and medical device users
Breast implants – patient perception of risk research
Information for patients, public and healthcare professionals
Access, new active substance and biosimilar work sharing initiatives
Information on applying for New Active Substance Work Sharing Initiative (NASWSI) and Biosimilar Work Sharing Initiative (BSWSI) assessments and list of approved products.